Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 9:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 124 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: L-Glutamine Clear all
Terminated Phase 2 Interventional Results available

Glutamine for the Prevention of Radiation Toxicity in Subjects Conserving Therapy

NCT02012608
View directory record Official record
Conditions
Breast Cancer
Interventions
Glutamine, Placebo
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Sep 2, 2026, 9:28 AM EDT
Terminated No phase listed Observational

Glutamine Challenge as Predictor of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt (TIPS)

NCT02026609
View directory record Official record
Conditions
Refractory Ascites, Hepatic Hydrothorax, Hepatic Encephalopathy, Cirrhosis
Interventions
Oral glutamine challenge, Psychometric Tests
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2017 · Synced Sep 2, 2026, 9:28 AM EDT
Completed Phase 1 Interventional

Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer

NCT04634539
View directory record Official record
Conditions
Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
Interventions
Gemcitabine, Nab-paclitaxel, L-glutamine
Drug
Lead sponsor
Jun Gong, MD
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Beverly Hills, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 2, 2026, 9:28 AM EDT
Completed Phase 4 Interventional

Glutamine Popsicles in Bone Marrow Transplant (BMT)/Hematopoietic Stem Cell Transplant (HSCT) Patients

NCT00204958
View directory record Official record
Conditions
Bone Marrow Transplantation, Hematopoietic Stem Cell Transplantion
Interventions
nutritional supplement, glutamine popsicle
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
4 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 30, 2015 · Synced Sep 2, 2026, 9:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Beverage Hydration Index of Different Solutions

NCT07507344
View directory record Official record
Conditions
Hydration
Interventions
Hydramin hydration solution, Carbohydrate and Electrolyte hydration solution, Water
Dietary Supplement
Lead sponsor
University of Memphis
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 2, 2026, 9:28 AM EDT
Completed Phase 4 Interventional Results available

The Effects of Eszopiclone and Lexapro on Prefrontal Glutamate and GABA in Depression With Anxiety and Insomnia

NCT00826111
View directory record Official record
Conditions
Depression, Anxiety, Insomnia
Interventions
Eszopiclone, Placebo
Drug
Lead sponsor
Steward St. Elizabeth's Medical Center of Boston, Inc.
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2012 · Synced Sep 2, 2026, 9:28 AM EDT
Completed Phase 1 Interventional

Novel Type 2 Diabetes Mellitus Preventive Therapies

NCT02351323
View directory record Official record
Conditions
Diabetes
Interventions
Glutamine (Pharmacological doses), Lifestyle change
Drug · Behavioral
Lead sponsor
Boston Medical Center
Other
Eligibility
12 Years to 19 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2015 · Synced Sep 2, 2026, 9:28 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Mechanisms of GLN Dipeptide in the SICU

NCT00248638
View directory record Official record
Conditions
Critical Illness
Interventions
Glutamine dipeptide with 15% Clinisol, 15% Clinisol
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 90 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
5
States / cities
Denver, Colorado • Atlanta, Georgia • Providence, Rhode Island + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 2, 2026, 9:28 AM EDT
Completed Phase 2 Interventional

Glutamine in Treating Side Effects in Children Who Are Undergoing Stem Cell Transplantation

NCT00003898
View directory record Official record
Conditions
Oral Complications, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
glutamine
Dietary Supplement
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
1 Year to 21 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
2
States / cities
Buffalo, New York • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2011 · Synced Sep 2, 2026, 9:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Metabolic Processes in Adults and Adolescents With Autism Spectrum Disorder

NCT02733120
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
stable isotope infusion
Other
Lead sponsor
Texas A&M University
Other
Eligibility
16 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 2, 2026, 9:28 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype

NCT02589145
View directory record Official record
Conditions
Lymphoma
Interventions
Lenalidomide, Vorinostat, Gemcitabine, Busulfan, Melphalan, Rituximab, Dexamethasone, Caphosol, Glutamine, Pyridoxine, Enoxaparin, Stem Cell Transplant, Palifermin
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Sep 2, 2026, 9:28 AM EDT
Completed Phase 2 Interventional Results available

CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)

NCT03163667
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
Placebo, CB-839, everolimus
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
38
States / cities
Tucson, Arizona • Rogers, Arkansas • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Sep 2, 2026, 9:28 AM EDT
Completed Phase 2 Interventional Results available

Glutamine for the Treatment of Patients With Irritable Bowel Syndrome

NCT01414244
View directory record Official record
Conditions
Diarrhea-Predominant Irritable Bowel Syndrome
Interventions
Glutamine
Drug
Lead sponsor
Tulane University
Other
Eligibility
18 Years to 72 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Sep 2, 2026, 9:28 AM EDT
Completed Phase 2 Interventional Results available

CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma

NCT03428217
View directory record Official record
Conditions
Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Interventions
CB-839, Cabozantinib, Placebo
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
59
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2023 · Synced Sep 2, 2026, 9:28 AM EDT
Recruiting Phase 1 Interventional

[18F] F-GLN by PET/CT in Breast Cancer

NCT03863457
View directory record Official record
Conditions
Breast Cancer
Interventions
Fluoroglutamine [18F]F-GLN
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 2, 2026, 9:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety Evaluation of a Diet and Nutritional Supplementation Program- Purify 2.0

NCT03685552
View directory record Official record
Conditions
Gastrointestinal Symptoms
Interventions
Prog: Purify-2
Other
Lead sponsor
Nature's Sunshine Products, Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lehi, Utah
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Sep 2, 2026, 9:28 AM EDT
Recruiting Early Phase 1 Interventional

L-Theanine to Support Relaxation and Mood for Cancer Patients in Surveillance

NCT07220447
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Survey Administration, Theanine
Other · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Duarte, California • Huntington Beach, California • Irvine, California
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 2, 2026, 9:28 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Prandial Metabolic Phenotype in Adults

NCT05400733
View directory record Official record
Conditions
Protein Metabolism
Interventions
Total Amino Acids, Essential Amino Acids, Essential Amino Acids + Hydroxy-methylbutyric acid (HMB), Essential Amino Acids + Leucine, Essential Amino Acids High, Placebo Water
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
60 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 2, 2026, 9:28 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Supplementation of Glutamine and Fish Oil Versus Placebo in Patients With Heart Failure

NCT01534663
View directory record Official record
Conditions
Heart Failure
Interventions
Glutamine and Fish Oil Supplementation, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
35 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Sep 2, 2026, 9:28 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia

NCT01179217
View directory record Official record
Conditions
Sickle Cell Anemia, Sickle ß0-Thalassemia
Interventions
L-glutamine, Placebo
Drug
Lead sponsor
Emmaus Medical, Inc.
Industry
Eligibility
5 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
31
States / cities
Mobile, Alabama • Phoenix, Arizona • Inglewood, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Sep 2, 2026, 9:28 AM EDT
Completed Not applicable Interventional

Effect of BKR-013 on Average Daily Glucose Levels

NCT03382015
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
BKR-013 or Placebo
Other
Lead sponsor
BioKier Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Sep 2, 2026, 9:28 AM EDT
Completed Not applicable Interventional Results available

Biological Response of Trauma Patients to Standard Trauma Resuscitation Therapy

NCT01239680
View directory record Official record
Conditions
Hemorrhagic Shock
Interventions
Glutamine, Ringer's Lactate, Placebo (for Glutamine)
Drug
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
21 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 16, 2014 · Synced Sep 2, 2026, 9:28 AM EDT
Completed Phase 1 Interventional

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

NCT02071862
View directory record Official record
Conditions
Solid Tumors, Triple-Negative Breast Cancer, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Mesothelioma, Fumarate Hydratase (FH)-Deficient Tumors, Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST), Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors, Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations, Tumors Harboring Amplifications in the cMyc Gene
Interventions
CB-839, Pac-CB, CBE, CB-Erl, CBD, CB-Cabo
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
13
States / cities
San Francisco, California • Stanford, California • Sarasota, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Sep 2, 2026, 9:28 AM EDT
Withdrawn No phase listed Observational

Proline Metabolism in Severely Burned Patients: Effect of Modulated Parenteral Feeding

NCT00216983
View directory record Official record
Conditions
Burns
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Sep 2, 2026, 9:28 AM EDT